Watchlist Price Alert

Inovio Pharmaceuticals In... (INO)

NASDAQ: INO · Real-Time Price · USD

1.89

-0.03 (-1.56%)

At close: May 14, 2025, 3:59 PM

1.91

1.06%

After-hours: May 14, 2025, 07:59 PM EDT

-1.56% (1D)

Bid	1.84
Market Cap	69.31M
Revenue (ttm)	217.76K
Net Income (ttm)	-25.25B
EPS (ttm)	-3.95
PE Ratio (ttm)	-0.48
Forward PE	-0.87
Analyst	Hold

Ask	1.93
Volume	777,903
Avg. Volume (20D)	656,486
Open	1.92
Previous Close	1.92
Day's Range	1.78 - 2.00
52-Week Range	1.42 - 13.44
Beta	1.41

About INO

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol INO

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for INO stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Inovio Pharmaceuticals has released their quartely earnings on May 13, 2025:

Revenue of $65.34K exceeds estimates by $55.34K, with Infinity% YoY growth.

EPS of -0.51 exceeds estimates by 0.23, with 61.07% YoY growth.

Why Price Moved

1 month ago

-1.7%

Shares of industrial stocks are trading lower foll... Unlock content with Pro Subscription

4 months ago

+18.13%

Shares of vaccine makers are trading higher after the first bird flu death was reporting in the US. Additionally, a recent CDC report noted an increase in acute respiratory illness activity.

News

1 day ago · seekingalpha.com

Inovio Pharmaceuticals, Inc. (INO) Q1 2025 Earnings Call Transcript

Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) Q1 2025 Earnings Conference Call May 13, 2025 4:30 PM ET Company Participants Jennie Willson - IR Jacqui Shea - President & CEO Mike Sumner - Chief Medical O...

1 day ago · zacks.com

Inovio Pharmaceuticals (INO) Reports Q1 Loss, Tops Revenue Estimates

Inovio Pharmaceuticals (INO) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.74. This compares to loss of $1.31 per share a year ago.

5 days ago · seekingalpha.com

Inovio Pharmaceuticals, Inc. (INO) Citizens JMP Life Sciences Conference (Transcript)

Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) Citizens JMP Life Sciences Conference May 8, 2025 11:30 AM ET Company Participants Jacqui Shea - President and CEO Mike Sumner - Chief Medical Officer Confer...

3 weeks ago · zacks.com

Bet on These 5 Top-Ranked Stocks With Rising P/E

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include Carvana, Context Therapeutics Inc, Inovio Pharmaceuticals, ChargePoint and MSA Safety Inc.

1 month ago · zacks.com

Inovio (INO) Upgraded to Buy: Here's What You Should Know

Inovio (INO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

1 month ago · zacks.com

Down -11.41% in 4 Weeks, Here's Why You Should You Buy the Dip in Inovio (INO)

Inovio (INO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates cou...

1 month ago · seekingalpha.com

Inovio Pharmaceuticals, Inc. (INO) Q4 2024 Earnings Call Transcript

Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) Q4 2024 Earnings Conference Call March 18, 2025 4:30 PM ET Company Participants Jennie Willson - IR Jacqui Shea - President & CEO Mike Sumner - Chief Medical...